Deal Structuring
Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. The optimal structure can significantly impact the financial and tax implications for both parties involved and the likelihood of regulatory approval.
The choice between an all-cash transaction, a stock swap, or a combination thereof is influenced by factors such as the buyer’s and seller’s financial positions and their desired level of risk. Cash transactions offer immediate liquidity to the seller but may trigger significant tax liabilities. Stock swaps can provide tax benefits but may dilute the buyer’s ownership stake. A combination of cash and stock can offer a compromise, allowing for a balance of liquidity, tax efficiency, and ownership considerations.
Earn-out provisions, where a portion of the purchase price is deferred and paid upon achieving specific performance targets, can also align the interests of buyers and sellers. These structures are particularly relevant in dealing with uncertainty about the future commercial potential of the target’s products. By linking a portion of the purchase price to future sales or profitability, earn-outs can incentivize the seller to continue driving the success of the acquired assets while providing the buyer with downside protection.
Tax optimization strategies are another crucial aspect of deal structuring. Depending on the jurisdiction and the specific assets involved, various tax structures, such as asset purchases or stock purchases, may be employed to minimize the tax burden for both parties. In some cases, complex tax structures involving offshore entities or hybrid financing arrangements may be utilized to achieve significant tax savings. However, ensuring that these structures comply with applicable tax laws and regulations is essential to avoid potential legal and reputational risks.
Intellectual Property Valuation
Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company’s value. This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. Sophisticated valuation methodologies, such as the income, market, and cost approaches, are employed to estimate the fair value of individual patents or the entire IP portfolio.
For example, Gilead Sciences’ acquisition of Immunomedics in 2020 included Trodelvy, an antibody-drug conjugate approved for treating triple-negative breast cancer. The IP surrounding Trodelvy, including patents covering the drug’s composition, manufacturing process, and clinical use, was a significant valuation component. Gilead’s assessment of the IP portfolio would have involved a detailed analysis of the patent claims, the remaining patent life, the potential for generic or biosimilar competition, and the expected revenue streams from Trodelvy in various markets. This comprehensive evaluation would have informed Gilead’s decision to acquire Immunomedics at a premium price, reflecting the significant value attributed to Trodelvy’s intellectual property.
Emerging Markets
Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity. The growing middle class and government initiatives to improve access to medicines have created an ecosystem for pharmaceutical companies seeking growth opportunities. Acquisitions in these markets offer several strategic advantages, including access to established distribution networks and a foothold in markets with significant untapped potential. For example, Takeda Pharmaceutical’s $62 billion acquisition of Shire plc in 2018 expanded its global footprint and tapped into Shire’s strong presence in emerging markets.
The Evolving Regulatory System
Regulatory frameworks play a pivotal role in shaping the pharmaceutical M&A landscape. Recent changes in drug approval processes, intellectual property laws, and pricing regulations have introduced both opportunities and challenges for dealmakers. The FDA’s accelerated approval pathways, such as the Breakthrough Therapy designation and the Priority Review program, have shortened development timelines and reduced costs for certain drugs, making them more attractive acquisition targets.
However, heightened regulatory scrutiny of mega-mergers, particularly about antitrust concerns, has created a more complex and uncertain environment for dealmakers. In 2021, the Federal Trade Commission (FTC) filed a lawsuit to block Illumina’s proposed $7.1 billion acquisition of Grail, a cancer-detection test developer. The FTC argued that the deal would stifle competition in the nascent market for multi-cancer early detection tests, potentially hindering innovation and raising consumer prices. While the deal ultimately went through in Europe, it remains blocked in the U.S. pending further litigation, illustrating the increasing regulatory challenges faced by pharmaceutical companies pursuing large-scale mergers.
Current Popularity of Mega-Mergers in Pharmaceutical M&A
The past decade has seen a notable wave of mega-mergers, defined as deals exceeding one billion dollars. The $63 billion acquisition of Allergan by AbbVie in 2020 stands as a prime example. Motivated by the impending patent expiration for AbbVie’s blockbuster drug, Humira, this strategic investment diversified the company’s portfolio, granting it access to Allergan’s diverse range of products, including Botox and Vraylar.
Similarly, Bristol-Myers Squibb’s $74 billion acquisition of Celgene in 2019 was a calculated move to bolster its oncology portfolio, particularly in light of intensifying competition for its flagship immunotherapy drug, Opdivo. By acquiring Celgene, Bristol-Myers Squibb gained access to Revlimid, a highly lucrative multiple myeloma drug, and a portfolio of other promising cancer therapies.
Biotech Buyouts
Acquiring biotechnology firms presents a strategic opportunity for established pharmaceutical corporations to revitalize mature product portfolios and counteract failed drug development pipelines. The high costs associated with bringing a new drug to market, estimated to be over $2.6 billion, and the notoriously high failure rates in drug development have incentivized these companies to seek external innovation. By acquiring promising biotech firms, pharmaceutical companies can access novel drug candidates and specialized expertise, which can help accelerate time-to-market and mitigate the inherent risks associated with drug development.
These acquisitions are typically structured as a combination of milestone-based payments contingent on achieving specific clinical and regulatory milestones and royalties on future sales. For instance, Bristol-Myers Squibb’s $74 billion acquisition of Celgene in 2019 involved a complex structure of cash and stock, along with Contingent Value Rights (CVR). The CVR, valued at $9 per share, were tied to the achievement of regulatory milestones for three of Celgene’s pipeline drugs: ozanimod, liso-cel, and bb2121. This strategic acquisition not only bolstered Bristol-Myers Squibb’s oncology portfolio with blockbuster drugs like Revlimid but also provided it access to Celgene’s promising pipeline of next-generation cancer therapies, thus securing its long-term growth potential in this lucrative market.
For emerging biotechnology firms, the prospect of acquisition by a well-resourced pharmaceutical corporation often presents an attractive avenue for realizing significant financial returns and accelerating the development and commercialization of their innovative therapies. These deals usually provide a much-needed infusion of capital, enabling the acceleration of clinical trials and expansion of manufacturing capabilities. However, such acquisitions also entail significant risks for biotech firms. The loss of autonomy, potential shifts in research priorities dictated by the acquiring company, and the challenges of integrating disparate corporate cultures can all pose obstacles to successfully realizing the acquired technology’s full potential.
Divestments and Spin-offs
Divestments, the sale of non-core assets or business units, enable pharmaceutical companies to shed underperforming or non-strategic assets, thereby freeing up capital for reinvestment in higher-growth areas or debt reduction. Such transactions can result in a significant influx of cash, bolstering the company’s balance sheet and enhancing its financial flexibility. Furthermore, divestments can improve profitability metrics like return on assets and return on equity by eliminating underperforming assets and focusing on higher-margin businesses.
Johnson & Johnson’s decision to spin off its consumer health division, Kenvue, in 2023, which owns iconic brands like Band-Aid, Tylenol, and Listerine, is a prime example. This strategic move allowed Johnson & Johnson to concentrate on its core pharmaceutical and medical device businesses, which boast higher growth potential and profit margins. It also unlocks shareholder value by creating a separate, publicly traded entity.
Spin-offs involve creating a new, independent company from an existing division or business unit. This can be an attractive strategy when a business unit, while profitable, aligns differently from the parent company’s core strategic focus or is undervalued within the existing corporate structure. By spinning off the division, the parent company can unlock hidden value, as the newly independent entity may be valued more favourably by the market due to its focused business model and growth prospects. GlaxoSmithKline’s spin-off of its consumer healthcare division, Haleon, in 2022 is a case in point. This transaction created a new global leader in consumer healthcare and allowed GSK to focus on its core biopharmaceutical business, potentially leading to a higher valuation for both entities.
Next for Pharmaceutical M&A
In the next decade, the convergence of several trends will shape the pharmaceutical M&A landscape. The rise of personalized medicine, fueled by advancements in genomics and biomarker identification, will drive a surge in M&A activity targeting companies with expertise in precision therapies and companion diagnostics. The aging global population and the concomitant increase in chronic disease prevalence will intensify the focus on specialty therapeutics and rare diseases, where lucrative opportunities exist for high-margin products. Integrating artificial intelligence and machine learning into drug discovery and development will be a crucial catalyst for M&A as companies seek to leverage these technologies to accelerate R&D timelines and reduce costs.
While mega-mergers may persist, the industry is also expected to witness an increase in smaller, more strategic acquisitions to acquire specific assets or technologies. The regulatory landscape will continue to evolve, focusing on balancing innovation with affordability and accessibility, posing ongoing challenges and opportunities for dealmakers.
Stay informed by signing up for our newsletter, where you’ll gain early access to the latest insights, trends, and breakthroughs in drug discovery, powered by cutting-edge data and analysis from industry-leading experts.